PortfoliosLab logoPortfoliosLab logo
CNCR vs. GSKH
Performance
Return for Risk
Drawdowns
Volatility
Dividends

Performance

CNCR vs. GSKH - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Loncar Cancer Immunotherapy ETF (CNCR) and GSK plc ADRhedged ETF (GSKH). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period


CNCR

1D
0.00%
1M
0.00%
YTD
6M
1Y
3Y*
5Y*
10Y*

GSKH

1D
2.87%
1M
2.94%
YTD
9.90%
6M
10.56%
1Y
42.66%
3Y*
5Y*
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

CNCR vs. GSKH - Yearly Performance Comparison


Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

CNCR vs. GSKH — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CNCR

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.


GSKH
GSKH Risk / Return Rank: 5151
Overall Rank
GSKH Sharpe Ratio Rank: 5353
Sharpe Ratio Rank
GSKH Sortino Ratio Rank: 5656
Sortino Ratio Rank
GSKH Omega Ratio Rank: 5454
Omega Ratio Rank
GSKH Calmar Ratio Rank: 5151
Calmar Ratio Rank
GSKH Martin Ratio Rank: 4141
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CNCR vs. GSKH - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Loncar Cancer Immunotherapy ETF (CNCR) and GSK plc ADRhedged ETF (GSKH). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


CNCRGSKHDifference
Sharpe ratioReturn per unit of total volatility

Sortino ratioReturn per unit of downside risk

Omega ratioGain probability vs. loss probability

1.30

Calmar ratioReturn relative to maximum drawdown

2.31

Martin ratioReturn relative to average drawdown

6.06

CNCR vs. GSKH - Sharpe Ratio Comparison


Loading charts...

Drawdowns

CNCR vs. GSKH - Drawdown Comparison

The maximum CNCR drawdown since its inception was 0.00%, smaller than the maximum GSKH drawdown of -18.54%. Use the drawdown chart below to compare losses from any high point for CNCR and GSKH.


Loading charts...

Drawdown Indicators


CNCRGSKHDifference

Max Drawdown

Largest peak-to-trough decline

0.00%

-18.54%

+18.54%

Max Drawdown (1Y)

Largest decline over 1 year

-18.54%

Current Drawdown

Current decline from peak

0.00%

-11.62%

+11.62%

Average Drawdown

Average peak-to-trough decline

0.00%

-5.86%

+5.86%

Ulcer Index

Depth and duration of drawdowns from previous peaks

7.06%

Volatility

CNCR vs. GSKH - Volatility Comparison


Loading charts...

Volatility by Period


CNCRGSKHDifference

Volatility (1M)

Calculated over the trailing 1-month period

6.89%

Volatility (6M)

Calculated over the trailing 6-month period

18.67%

Volatility (1Y)

Calculated over the trailing 1-year period

0.00%

26.14%

-26.14%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

0.00%

26.95%

-26.95%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

0.00%

26.95%

-26.95%

CNCR vs. GSKH - Expense Ratio Comparison

CNCR has a 0.79% expense ratio, which is higher than GSKH's 0.19% expense ratio.


Dividends

CNCR vs. GSKH - Dividend Comparison

CNCR has not paid dividends to shareholders, while GSKH's dividend yield for the trailing twelve months is around 2.82%.


PositionTTM2025
CNCR
Loncar Cancer Immunotherapy ETF
0.00%0.00%
GSKH
GSK plc ADRhedged ETF
2.82%1.15%

Frequently Asked Questions


On fees, GSKH is cheaper at 0.19% per year. The better choice depends on whether you care most about return, fees, risk, or income.

GSKH is cheaper with a 0.19% expense ratio, compared with 0.79% for CNCR.

GSKH has the higher dividend yield at 2.82%, compared with 0.00% for CNCR.

CNCR tracks Loncar Cancer Immunotherapy Index, while GSKH tracks GSK plc Local Shares Total Return. They also come from different issuers: Exchange Traded Concepts and ADRhedged. Their fees differ too: 0.79% for CNCR and 0.19% for GSKH.

Portfolio Optimizer

Find the right allocation for CNCR and GSKH

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer